InvestorsHub Logo
Followers 146
Posts 27518
Boards Moderated 3
Alias Born 02/07/2004

Re: midastouch017 post# 56

Monday, 05/04/2015 9:18:15 AM

Monday, May 04, 2015 9:18:15 AM

Post# of 272
Ophthalix has signed a non-binding term sheet to acquire Israel-based Improved Vision Systems; terms not disclosed (OPLI) : I.V.S. develops breakthrough medical device technologies to improve sight, diagnose and offer therapy for a variety of ocular diseases including glaucoma, age related macular degeneration (AMD), diabetic retinopathy and oculo-motor pathologies. OphthaliX announced it is committed to continuing its development program for its drug candidate CF101, a neuro-protective and anti-inflammatory drug, for the treatment of glaucoma. Patients are currently enrolled for the second segment of the Phase II study and are treated orally with CF101.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MIGI News